An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The clinical development of an inhibitor of cellular proteasome function suggests that compounds targeting other components of the ubiquitin-proteasome system might prove useful for the treatment of human malignancies. NEDD8-activating enzyme (NAE) is an essential component of the NEDD8 conjugation pathway that controls the activity of the cullin-RING subtype of ubiquitin ligases, thereby regulating the turnover of a subset of proteins upstream of the proteasome. Substrates of cullin-RING ligases have important roles in cellular processes associated with cancer cell growth and survival pathways. Here we describe MLN4924, a potent and selective inhibitor of NAE. MLN4924 disrupts cullin-RING ligase-mediated protein turnover leading to apoptotic death in human tumour cells by a new mechanism of action, the deregulation of S-phase DNA synthesis. MLN4924 suppressed the growth of human tumour xenografts in mice at compound exposures that were well tolerated. Our data suggest that NAE inhibitors may hold promise for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“orthogonally confirmed dose-dependent KAT2A degradation by western blot, and demonstrated that this degradation can be rescued by pre-treatment with a UBA3/NAE1 inhibitor, MLN4924 (37), a proteasome inhibitor, bortezomib (38), and a competing CRBN ligand, pomalidomide (7) (Fig. 1D).”
From Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues (2026) · cites this paper as [37]
In the citing paper
“we cotreated cells with a proteasome inhibitor (bortezomib) or a NEDD8-activating enzyme E1 inhibitor (MLN-4924 32 ) and found that both inhibitors prevented degradation of BTK (Figure 2D).”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [32]
Citations
Cites
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Self-citationKobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27
Carrano, A. C., Eytan, E., Hershko, A., & Pagano, M. (1999) · Nature Cell Biology · doi:10.1038/12013 · Cited by 1,543
Modification of Proteins by Ubiquitin and Ubiquitin-Like Proteins
Kerscher, O., Felberbaum, R., & Hochstrasser, M. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010605.093503 · Cited by 1,517
Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., & Harper, J. W. (1999) · Genes & Development · doi:10.1101/gad.13.3.270 · Cited by 954
Duda, D. M., Borg, L. A., Scott, D. C., Hunt, H. W., Hammel, M., & Schulman, B. A. (2008) · Cell · doi:10.1016/j.cell.2008.07.022 · Cited by 767
Kamura, T., Sato, S., Iwai, K., Czyzyk-Krzeska, M., Conaway, R. C., & Conaway, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190332597 · Cited by 653
Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy
Kane, R. C., Bross, P. F., Farrell, A. T., & Pazdur, R. (2003) · The Oncologist · doi:10.1634/theoncologist.8-6-508 · Cited by 628
Cited by
Items 101–200 of 1,005
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
He, X., Riceberg, J., Soucy, T., Koenig, E., Minissale, J., Gallery, M., Bernard, H., Yang, X., Liao, H., Rabino, C., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2463 · Cited by 230
Self-citationTwo Distinct Types of E3 Ligases Work in Unison to Regulate Substrate Ubiquitylation
Scott, D. C., Rhee, D. Y., Duda, D. M., Kelsall, I. R., Olszewski, J. L., Paulo, J. A., de Jong, A., Ovaa, H., Alpi, A. F., Harper, J. W., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.027 · Cited by 229
Mechanism of CRL4Cdt2, a PCNA-dependent E3 ubiquitin ligase
Havens, C. G., & Walter, J. C. (2011) · Genes & Development · doi:10.1101/gad.2068611 · Cited by 224
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226
“MLN4924 [51] is an inhibitor of the NEDD8-activating enzyme (NAE), thus blocking cullins neddylation and inactivating cullin RING ligases (CRLs).”
BackgroundInfluentialThe NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy
Soucy, T. A., Dick, L. R., Smith, P. G., Milhollen, M. A., & Brownell, J. E. (2010) · Genes & Cancer · doi:10.1177/1947601910382898 · Cited by 225
Self-citationProtein neddylation and its alterations in human cancers for targeted therapy
Zhou, L., Zhang, W., Sun, Y., & Jia, L. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.01.009 · Cited by 226
Specific Small Molecule Inhibitors of Skp2-Mediated p27 Degradation
Wu, L., Grigoryan, A. V., Li, Y., Hao, B., Pagano, M., & Cardozo, T. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.09.015 · Cited by 219
Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
Soucy, T. A., Smith, P. G., & Rolfe, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0343 · Cited by 222
Self-citationFunctional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
The 26 S Proteasome: From Basic Mechanisms to Drug Targeting
Navon, A., & Ciechanover, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.018481 · Cited by 214
Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All
Desimmie, B. A., Delviks-Frankenberrry, K. A., Burdick, R. C., Qi, D., Izumi, T., & Pathak, V. K. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.10.033 · Cited by 201
Functional characterization of SOX2 as an anticancer target
Zhang, S., Xiong, X., & Sun, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00242-3 · Cited by 206
Polyubiquitylation drives replisome disassembly at the termination of DNA replication
Priego Moreno, S., Bailey, R., Campion, N., Herron, S., & Gambus, A. (2014) · Science · doi:10.1126/science.1253585 · Cited by 195
Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome
Cavadini, S., Fischer, E. S., Bunker, R. D., Potenza, A., Lingaraju, G. M., Goldie, K. N., Mohamed, W. I., Faty, M., Petzold, G., Beckwith, R. E. J., et al. (2016) · Nature · doi:10.1038/nature17416 · Cited by 213
Active site remodelling accompanies thioester bond formation in the SUMO E1
Olsen, S. K., Capili, A. D., Lu, X., Tan, D. S., & Lima, C. D. (2010) · Nature · doi:10.1038/nature08765 · Cited by 210
Xie, P., Zhang, M., He, S., Lu, K., Chen, Y., Xing, G., Lu, Y., Liu, P., Li, Y., Wang, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms4733 · Cited by 208
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207
Langston, S. P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.-C., Claiborne, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01491 · Cited by 203
Self-citationAbbas, T., Keaton, M. A., & Dutta, A. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012914 · Cited by 195
Strickson, S., Campbell, D. G., Emmerich, C. H., Knebel, A., Plater, L., Ritorto, M. S., Shpiro, N., & Cohen, P. (2013) · Biochemical Journal · doi:10.1042/bj20121651 · Cited by 200
Targeting the ubiquitin–proteasome system for cancer therapy
Shen, M., Schmitt, S., Buac, D., & Dou, Q. P. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.815728 · Cited by 197
High-Content Monitoring of Drug Effects in a 3D Spheroid Model
Mittler, F., Obeïd, P., Rulina, A. V., Haguet, V., Gidrol, X., & Balakirev, M. Y. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00293 · Cited by 194
Li, W., Li, F., Zhang, X., Lin, H.-K., & Xu, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00825-8 · Cited by 198
Swords, R. T., Coutre, S., Maris, M. B., Zeidner, J. F., Foran, J. M., Cruz, J., Erba, H. P., Berdeja, J. G., Tam, W., Vardhanabhuti, S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-805895 · Cited by 199
Scott, D. C., Sviderskiy, V. O., Monda, J. K., Lydeard, J. R., Cho, S. E., Harper, J. W., & Schulman, B. A. (2014) · Cell · doi:10.1016/j.cell.2014.04.037 · Cited by 201
Protein-protein interaction modulators: advances, successes and remaining challenges
Mabonga, L., & Kappo, A. P. (2019) · Biophysical Reviews · doi:10.1007/s12551-019-00570-x · Cited by 193
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Bai, L., Zhou, B., Yang, C.-Y., Ji, J., McEachern, D., Przybranowski, S., Jiang, H., Hu, J., Xu, F., Zhao, Y., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2622 · Cited by 199
DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
Zhang, X., Luukkonen, L. M., Eissler, C. L., Crowley, V. M., Yamashita, Y., Schafroth, M. A., Kikuchi, S., Weinstein, D. S., Symons, K. T., Nordin, B. E., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00990 · Cited by 199
White, E. A., Sowa, M. E., Tan, M. J. A., Jeudy, S., Hayes, S. D., Santha, S., Münger, K., Harper, J. W., & Howley, P. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116776109 · Cited by 198
“Cells were treated with MLN4924, an inhibitor of the NEDD8-activating enzyme (32), and protein complexes containing HA were immunopurified and analyzed by Western blotting.”
MethodTargeting cancer with small-molecule pan-KRAS degraders
Popow, J., Farnaby, W., Gollner, A., Kofink, C., Fischer, G., Wurm, M., Zollman, D., Wijaya, A., Mischerikow, N., Hasenoehrl, C., et al. (2024) · Science · doi:10.1126/science.adm8684 · Cited by 198
Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Yang, C., Yang, Y., Li, Y., Ni, Q., & Li, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10177 · Cited by 188
Cheng, M., Yu, X., Lu, K., Xie, L., Wang, L., Meng, F., Han, X., Chen, X., Liu, J., Xiong, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01566 · Cited by 189
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Wu, H.-L., Gong, Y., Ji, P., Xie, Y.-F., Jiang, Y.-Z., & Liu, G.-Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01263-x · Cited by 186
Kleiger, G., Saha, A., Lewis, S., Kuhlman, B., & Deshaies, R. J. (2009) · Cell · doi:10.1016/j.cell.2009.10.030 · Cited by 192
Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer
Li, L., Wang, M., Yu, G., Chen, P., Li, H., Wei, D., Zhu, J., Xie, L., Jia, H., Shi, J., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju083 · Cited by 188
Self-citationWang, J., Yu, X., Gong, W., Liu, X., Park, K.-S., Ma, A., Tsai, Y.-H., Shen, Y., Onikubo, T., Pi, W.-C., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00850-x · Cited by 181
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
Shah, J. J., Jakubowiak, A. J., O'Connor, O. A., Orlowski, R. Z., Harvey, R. D., Smith, M. R., Lebovic, D., Diefenbach, C., Kelly, K., Hua, Z., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1237 · Cited by 189
Self-citationNEDD8 Pathways in Cancer, Sine Quibus Non
Watson, I. R., Irwin, M. S., & Ohh, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.002 · Cited by 181
The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1204 · Cited by 182
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
Nawrocki, S. T., Griffin, P., Kelly, K. R., & Carew, J. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.707192 · Cited by 186
Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation
Lin, P. W., Myers, L. E. S., Ray, L., Song, S.-C., Nasr, T. R., Berardinelli, A. J., Kundu, K., Murthy, N., Hansen, J. M., & Neish, A. S. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.07.033 · Cited by 183
Synthetic Entries to and Biological Activity of Pyrrolopyrimidines
De Coen, L. M., Heugebaert, T. S. A., García, D., & Stevens, C. V. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00483 · Cited by 183
Targeted inhibition of the COP9 signalosome for treatment of cancer
Schlierf, A., Altmann, E., Quancard, J., Jefferson, A. B., Assenberg, R., Renatus, M., Jones, M., Hassiepen, U., Schaefer, M., Kiffe, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13166 · Cited by 190
Ubiquitin ligation to F-box protein targets by SCF–RBR E3–E3 super-assembly
Horn-Ghetko, D., Krist, D. T., Prabu, J. R., Baek, K., Mulder, M. P. C., Klügel, M., Scott, D. C., Ovaa, H., Kleiger, G., & Schulman, B. A. (2021) · Nature · doi:10.1038/s41586-021-03197-9 · Cited by 187
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 180
Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system
Wang, J., Li, B.-X., Ge, P.-P., Li, J., Wang, Q., Gao, G. F., Qiu, X.-B., & Liu, C. H. (2015) · Nature Immunology · doi:10.1038/ni.3096 · Cited by 183
Molecular docking for virtual screening of natural product databases
Ma, D.-L., Chan, D. S.-H., & Leung, C.-H. (2011) · Chem. Sci. · doi:10.1039/c1sc00152c · Cited by 175
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Wu, H., Yang, K., Zhang, Z., Leisten, E. D., Li, Z., Xie, H., Liu, J., Smith, K. A., Novakova, Z., Barinka, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00516 · Cited by 180
Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Micel, L. N., Tentler, J. J., Smith, P. G., & Eckhardt, G. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0958 · Cited by 176
Self-citationVan Nguyen, T., Lee, J. E., Sweredoski, M. J., Yang, S.-J., Jeon, S.-J., Harrison, J. S., Yim, J.-H., Lee, S. G., Handa, H., Kuhlman, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.032 · Cited by 177
“addition of the proteasome inhibitor bortezomib or the NEDD8-activating enzyme inhibitor MLN4924 (Figure 2B), which inactivates Cullin-RING E3 ubiquitin ligase activity (Soucy et al., 2009).”
C-Terminal End-Directed Protein Elimination by CRL2 Ubiquitin Ligases
Lin, H.-C., Yeh, C.-W., Chen, Y.-F., Lee, T.-T., Hsieh, P.-Y., Rusnac, D. V., Lin, S.-Y., Elledge, S. J., Zheng, N., & Yen, H.-C. S. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.04.006 · Cited by 169
STAT3 regulated ARF expression suppresses prostate cancer metastasis
Pencik, J., Schlederer, M., Gruber, W., Unger, C., Walker, S. M., Chalaris, A., Marié, I. J., Hassler, M. R., Javaheri, T., Aksoy, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms8736 · Cited by 170
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171
“18,350,365 Finally, the most frequent cell cycle arrest induced by MLN4924 is at the G2 or G2/M phase by inactivation of CRL1 to cause the accumulation of Wee1, an inhibitor of G2 –”
BackgroundInfluentialHaven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Sarantopoulos, J., Shapiro, G. I., Cohen, R. B., Clark, J. W., Kauh, J. S., Weiss, G. J., Cleary, J. M., Mahalingam, D., Pickard, M. D., Faessel, H. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1338 · Cited by 167
Self-citationBruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Wei, D., Li, H., Yu, J., Sebolt, J. T., Zhao, L., Lawrence, T. S., Smith, P. G., Morgan, M. A., & Sun, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2866 · Cited by 164
Self-citationNeddylation of PTEN regulates its nuclear import and promotes tumor development
Xie, P., Peng, Z., Chen, Y., Li, H., Du, M., Tan, Y., Zhang, X., Lu, Z., Cui, C.-P., Liu, C. H., et al. (2021) · Cell Research · doi:10.1038/s41422-020-00443-z · Cited by 164
Hypoxia and Innate Immunity: Keeping Up with the HIFsters
Colgan, S. P., Furuta, G. T., & Taylor, C. T. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100819-121537 · Cited by 160
c-Cbl-Mediated Neddylation Antagonizes Ubiquitination and Degradation of the TGF-β Type II Receptor
Zuo, W., Huang, F., Chiang, Y. J., Li, M., Du, J. C., Ding, Y., Zhang, T., Lee, H. W., Jeong, L. S., Chen, Y., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.002 · Cited by 162
Milhollen, M. A., Narayanan, U., Soucy, T. A., Veiby, P. O., Smith, P. G., & Amidon, B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2122 · Cited by 159
Self-citationControl of cell growth by the SCF and APC/C ubiquitin ligases
Skaar, J. R., & Pagano, M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.08.004 · Cited by 181
From Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 166
Keap1/Cullin3 Modulates p62/SQSTM1 Activity via UBA Domain Ubiquitination
Lee, Y., Chou, T.-F., Pittman, S. K., Keith, A. L., Razani, B., & Weihl, C. C. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.030 · Cited by 154
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 153
Jia, L., Li, H., & Sun, Y. (2011) · Neoplasia · doi:10.1593/neo.11420 · Cited by 159
Ubiquitylation, neddylation and the DNA damage response
Brown, J. S., & Jackson, S. P. (2015) · Open Biology · doi:10.1098/rsob.150018 · Cited by 147
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Xiong, Y., Zhong, Y., Yim, H., Yang, X., Park, K.-S., Xie, L., Poulikakos, P. I., Han, X., Xiong, Y., Chen, X., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09255 · Cited by 154
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
Larsson, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.005 · Cited by 173
Blackburn, C., Gigstad, K. M., Hales, P., Garcia, K., Jones, M., Bruzzese, F. J., Barrett, C., Liu, J. X., Soucy, T. A., Sappal, D. S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100383 · Cited by 163
Self-citationPathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies
Lim, K., Yang, Y., & Staudt, L. M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01105.x · Cited by 157
Targeting the ubiquitin pathway for cancer treatment
Liu, J., Shaik, S., Dai, X., Wu, Q., Zhou, X., Wang, Z. P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.005 · Cited by 155
CRL4Cdt2: Master coordinator of cell cycle progression and genome stability
Abbas, T., & Dutta, A. (2011) · Cell Cycle · doi:10.4161/cc.10.2.14530 · Cited by 163
SCF E3 Ubiquitin Ligases as Anticancer Targets
Jia, L., & Sun, Y. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519734 · Cited by 147
Lightcap, E. S., Yu, P., Grossman, S., Song, K., Khattar, M., Xega, K., He, X., Gavin, J. M., Imaichi, H., Garnsey, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba7791 · Cited by 162
Self-citationZhao, Y., Xiong, X., Jia, L., & Sun, Y. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.125 · Cited by 158
Kato, J., & Yoneda‐Kato, N. (2009) · Genes to Cells · doi:10.1111/j.1365-2443.2009.01349.x · Cited by 141
Mészáros, B., Kumar, M., Gibson, T. J., Uyar, B., & Dosztányi, Z. (2017) · Science Signaling · doi:10.1126/scisignal.aak9982 · Cited by 157
Aghajan, M., Jonai, N., Flick, K. M., Fu, F., Luo, M., Cai, X., Ouni, I., Pierce, N. W., Tang, X., Lomenick, B., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1645 · Cited by 144
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
Zhang, X., Linder, S. T., & Bazzaro, M. (2020) · Cancers · doi:10.3390/cancers12040902 · Cited by 157
The ribotoxic stress response drives UV-mediated cell death
Sinha, N. K., McKenney, C. D., Yeow, Z. Y., Li, J. J., Nam, K. H., Yaron, T. M., Johnson, J. L., Huntsman, E. M., Cantley, L. C., Ordureau, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.018 · Cited by 144
Composition and Regulation of the Cellular Repertoire of SCF Ubiquitin Ligases
Reitsma, J. M., Liu, X., Reichermeier, K. M., Moradian, A., Sweredoski, M. J., Hess, S., & Deshaies, R. J. (2017) · Cell · doi:10.1016/j.cell.2017.10.016 · Cited by 142
Popow, J., Arnhof, H., Bader, G., Berger, H., Ciulli, A., Covini, D., Dank, C., Gmaschitz, T., Greb, P., Karolyi-Özguer, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01826 · Cited by 138
Neddylation Promotes Ubiquitylation and Release of Ku from DNA-Damage Sites
Brown, J. S., Lukashchuk, N., Sczaniecka-Clift, M., Britton, S., le Sage, C., Calsou, P., Beli, P., Galanty, Y., & Jackson, S. P. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.058 · Cited by 152
Genetic interactions of G-quadruplexes in humans
Zyner, K. G., Mulhearn, D. S., Adhikari, S., Cuesta, S. M., Antonio, M. D., Erard, N., Hannon, G. J., Tannahill, D., & Balasubramanian, S. (2019) · eLife · doi:10.7554/elife.46793 · Cited by 145
Self-citationHypoxia and Mucosal Inflammation
Colgan, S. P., Campbell, E. L., & Kominsky, D. J. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044231 · Cited by 132
FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4
Zhang, Q., Karnak, D. M., Tan, M., Lawrence, T. S., Morgan, M. A., & Sun, Y. (2016) · Molecular Cell · doi:10.1016/j.molcel.2015.12.010 · Cited by 145
Embade, N., Fernández‐Ramos, D., Varela‐Rey, M., Beraza, N., Sini, M., de Juan, V. G., Woodhoo, A., Martínez-López, N., Iruretagoyena, B. R., Bustamante, J., et al. (2011) · Hepatology · doi:10.1002/hep.24795 · Cited by 146
Ubiquitination and Degradation of the Inhibitors of NF- B
Kanarek, N., London, N., Schueler‐Furman, O., & Ben‐Neriah, Y. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000166 · Cited by 161
The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions
Leidecker, O., Matić, I., Mahata, B., Pion, E., & Xirodimas, D. P. (2012) · Cell Cycle · doi:10.4161/cc.11.6.19559 · Cited by 134
Akt: a key transducer in cancer
Tsai, P., Lai, Y., Manne, R., Tsai, Y.-S., Sarbassov, D. D., & Lin, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00860-9 · Cited by 143
Therapeutic strategies within the ubiquitin proteasome system
Eldridge, A. G., & O’Brien, T. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.82 · Cited by 142
Zhou, W., Xu, J., Li, H., Xu, M., Chen, Z. J., Wei, W., Pan, Z., & Sun, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1585 · Cited by 133
Targeting SUMO Signaling to Wrestle Cancer
Kroonen, J. S., & Vertegaal, A. C. O. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.009 · Cited by 145
Adès, L., Girshova, L., Doronin, V. A., Díez-Campelo, M., Valcárcel, D., Kambhampati, S., Viniou, N.-A., Woszczyk, D., De Paz Arias, R., Symeonidis, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007334 · Cited by 130
“Pevonedistat is a selective inhibitor of NEDD8-activating enzyme, 18,19 which is required for ubiquitination and degradation of select proteins to maintain protein homeostasis.”
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Kikuchi, J., Wada, T., Shimizu, R., Izumi, T., Akutsu, M., Mitsunaga, K., Noborio, K., Nobuyoshi, M., Ozawa, K., Kano, Y., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235663 · Cited by 139
Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021) · Cells · doi:10.3390/cells10081879 · Cited by 140
Metadata
- Authors
- Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., Cullis, C. A., Doucette, A., Garnsey, J. J., Gaulin, J. L., Gershman, R. E., Lublinsky, A. R., McDonald, A., Mizutani, H., Narayanan, U., Olhava, E. J., Peluso, S., Rezaei, M., Sintchak, M. D., Talreja, T., Thomas, M. P., Traore, T., Vyskocil, S., Weatherhead, G. S., Yu, J., Zhang, J., Dick, L. R., Claiborne, C. F., Rolfe, M., Bolen, J. B., & Langston, S. P.
- Affiliations
- Takeda Oncology (United States) (US)
- Corresponding author
- Soucy, Teresa A.
- ORCID
- Venue
- Nature
- Published
- 2009-04
- Volume
- 458
- Issue
- 7239
- Pages
- 732-736
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2076194625
- Cited by
- 1,990
- References
- 46
- Citations by year
- 2026: 110 · 2025: 120 · 2024: 156 · 2023: 126 · 2022: 137 · 2021: 155 · 2020: 170 · 2019: 149 · 2018: 112 · 2017: 105 · 2016: 108 · 2015: 98 · 2014: 99 · 2013: 100 · 2012: 100
- FWCI
- 32.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- NEDD8-activating enzyme, MLN4924, cullin-RING ubiquitin ligases, ubiquitin-proteasome system, proteasome inhibitors, cancer cell death, tumor xenografts, small molecule inhibitors, antitumour activity
- MeSH terms
- NEDD8 Protein, Animals, Antineoplastic Agents, Cells, Cultured, Cyclopentanes, Enzyme Inhibitors, Female, Humans, Neoplasms, Pyrimidines, Transplantation, Heterologous, Ubiquitins, Ubiquitin-Activating Enzymes, Cullin Proteins, Cell Line, Tumor, Mice, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.